Effects of Bosentan on the Skin Temperature of Hands and Feet in Patients with Connective Tissue Diseases Complicated with Raynauds Phenomenon: A Prospective, Open-Label, Uncontrolled, Single-Center Study

Yuji Akiyama

Authors

Yuji Akiyama

Keywords:

digital ulcers, endothelin receptor antagonist, pulmonary arterial hypertension, secondary Raynaud#x2019;s phenomenon, systemic sclerosis, thermography

Abstract

Abstract not found

Downloads

How to Cite

Effects of Bosentan on the Skin Temperature of Hands and Feet in Patients with Connective Tissue Diseases Complicated with Raynauds Phenomenon: A Prospective, Open-Label, Uncontrolled, Single-Center Study. (2015). Global Journal of Medical Research, 15(14), 7-15. https://medicalresearchjournal.org/index.php/GJMR/article/view/

Download Citation

References

Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. 332(6163), 411-415.

Dhillon S. (2009) Bosentan A review of its use in the management of digital ulcers associated with systemic sclerosis. 69(14), 2005-14.

Y. Shirai, H. Yasuoka, Y. Okano, T. Takeuchi, T. Satoh, M. Kuwana (2012) Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a single-centre cohort. 51(10), 1846-1854.

(1996) Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud's phenomenon. 23, 1917-20.

M. Hettema, D. Zhang, H. Bootsma, Cgm Kallenberg (2007) Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis. 66, 1398-1399.

Funauchi M, Kishimoto K, Shimizu H, Nagare Y, Hino S, Yano T (2009) Effects of bosentan on the skin lesions: an observational study from a single center in Japan. 29, 769-775.

Giordano N, Puccetti L, Papakostas P, Dipietra N, Bruni F, Pasqui AL (2010) Bosentan Treatment for Raynaud's Phenomenon and Skin Fibrosis in Patients with Systemic Sclerosis and Pulmonary Arterial Hypertension: An Open-Label, Observational, Retrospective Study. 23(4), 1185-1193.

V. Nguyen, K. Eisendle, I. Gruber, B. Hugl, D. Reider, N. Reider (2010) Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study. 49(3), 583-588.

Rosato E, Molinaro I, Borghese F, Rossi C, ZPisarri S, Salsano F (2010) Bosentan Improves Skin Perfusion of Hands in Patients with Systemic Sclerosis with Pulmonary Arterial Hypertension. 37(12), 2531-2539.

T. Moore, A. Vail, A. Herrick (2007) Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud's phenomenon. 46, 363-364.

Parisi S, Peroni CL, Lagana A, Scarati M, Ambrogio F, Bruzzone M (2013) Efficacy of ambrisentan in the treatment of digital ulcers in patients with systemic sclerosis: a preliminary study. 52, 1142 4.

(1980) Preliminary criteria for the classication of systemic sclerosis (scleroderma). 23(5), 581-90.

Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. 25(11), 1271-1277.

Kasukawa R, Tojo T, Miyawaki S (1988) Mixed connective tissue disease: preliminary diagnostic criteria. 1, 263-267.

Bohan A, Peter JB (1975) Polymyositis and Dermatomyositis. 292, 403-407.

Rodeheffer RJ, Rommer JA, Wigley F, Smith CR (1983) Controlled Double-Blind Trial of Nifedipine in the Treatment of Raynaud's Phenomenon. 308(15), 880-883.

Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI (2001) Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. 40, 1038-1043.

Y. Akiyama, S. Ohno, T. Asaoka, T. Katagiri, M. Takeishi, H. Omata (2001) The combination therapy with sarpoglerate hydrochloride and kampo medicine (Oren-gedoku-to or Toki-shakuyaku-san) for Raynaud's phenomenon. 51(5), 1101-1108.

M. Ramos-Casals, P. Brito-Zeron, N. Nardi, G. Claver, G. Risco, F. Parraga (2004) Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis. 43, 1454-1456.

N. Selenko-Gebauer, N. Duschek, G. Minimair, G. Stingl, F. Karlhofer (2006) Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan. 45(Supplement 3), iii45-iii48. https://doi.org/10.1093/rheumatology/kel290

Shenoy PD, Kumar S, Jha LK, Choudhary SK, Singh U, Misra R Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. 49(12), 2420-2428.

Roustit M, Blaise S, Allanore Y, Carpentier PH, Caglayan E, Cracowski JL (2013) Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. 72, 1696-1699.

Corallo C, Pecetti CC, Iglarz M, Volpi N, Franci D, Montella A (2013) Macitentan slows down the dermal fibrotic process in systemic sclerosis: in vitro findings. 27(2), 455-462.